- GlobeNewswire•2 days agoCempra to Present Solithromycin at FDA Antimicrobial Drugs Advisory Committee Meeting on November 4, 2016
CHAPEL HILL, N.C., Aug. 30, 2016-- Cempra, Inc., a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, ...
- 24/7 Wall St.•2 days ago
Everybody likes to look for the home run stocks, and with good reason. Hitting the long ball on a stock pick brings in stellar capital gains and can help a moribund portfolio look real good, real fast....
- GlobeNewswire•6 days agoCempra’s Pivotal Phase 3 SOLITAIRE-IV Study of IV to Oral Solithromycin Published in Clinical Infectious Diseases
—Both pivotal Phase 3 studies now published in leading infectious disease journals—. —FDA and EMA currently reviewing marketing applications for solithromycin for CABP in U.S. and EU—. CHAPEL HILL, N.C., ...
Cempra, Inc. (CEMP)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||21.49 x 200|
|Ask||22.32 x 100|
|Day's Range||21.50 - 22.47|
|52wk Range||14.03 - 39.25|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-9.84|
|Avg Vol (3m)||744,356|
|Dividend & Yield||N/A (N/A)|